글로벌 로타바이러스 예방 시장 – 2029년까지의 산업 동향 및 예측

시장 분석 및 규모

최근 몇 년 동안 로타바이러스 예방 시장은 예측 기간 동안 빠르게 성장할 것으로 예상됩니다. 로타바이러스는 어린이와 신생아에게 쉽게 감염되는 바이러스 입니다. 심한 물설사 , 발열, 구토, 복통은 모두 감염 증상입니다. 미국에서는 출생 후 5년 이내에 거의 모든 어린이가 적어도 한 번은 로타바이러스에 감염되고, 40만 명 이상의 어린이가 치료를 위해 의사에게 보내지며, 매년 약 50~60명의 어린이가 사망합니다.

Data Bridge Market Research는 로타바이러스 예방 시장이 2021년에 74억 1,500만 달러 규모였으며 2029년까지 1,566억 달러에 도달할 것으로 예상하고 2022년부터 2029년까지의 예측 기간 동안 9.80%의 CAGR을 기록할 것으로 분석했습니다. Data Bridge Market Research 팀이 큐레이팅한 시장 보고서에는 심층적인 전문가 분석, 환자 역학, 파이프라인 분석, 가격 분석 및 규제 프레임워크가 포함되어 있습니다.

시장 정의

로타바이러스는 설사와 탈수를 유발하는 레오바이러스과에 속하는 백신 예방 가능 바이러스입니다. 감염된 사람이나 오염된 표면을 통해 퍼집니다. 발열과 구토는 로타바이러스 감염 환자가 경험하는 첫 징후와 증상입니다. 로타바이러스 감염은 불쾌하지만, 일반적으로 탈수를 피하기 위해 물을 많이 마셔서 집에서 치료할 수 있습니다. 심각한 탈수는 병원에서 정맥 주사로 체액을 주입해야 할 수도 있습니다.

보고 범위 및 시장 세분화

Rotavirus Prophylaxis Market Dynamics

Drivers

• Increasing prevalence of rotavirus infection

The rising prevalence of rotavirus infection is anticipated to propel the rotavirus prophylaxis market's growth rate. Because of their poor hygiene habits, rotavirus sickness is highly contagious and spreads quickly among children. In hospitals as well as day-care centres, rotavirus infection is a widespread healthcare issue. Another factor driving the rotavirus vaccine market is support from UNICEF and GAVI (a vaccine alliance of multiple countries under which 45 countries have been approved for rotavirus vaccine support) for large-scale vaccination, supply availability, and access to affordable prices.

• Increasing investment for healthcare infrastructure

Another significant factor influencing the growth rate of rotavirus prophylaxis market is the rising healthcare expenditure which helps in improving its infrastructure.  

Furthermore, rising initiatives by public and private organizations to spread awareness will expand the rotavirus prophylaxis market. Additionally, high disposable income and continuously changing lifestyle pf people will result in the expansion of rotavirus prophylaxis market. Along with this, favourable government policies are estimated to enhance the market's growth rate.

Opportunities

• Increase in the number of research and development activities       

The market's growth is fueled by an increase in the number of research and development activities. This will provide beneficial opportunities for the rotavirus prophylaxis market growth. Along with this, rising drug approvals and launches will further propel the market’s growth rate.

Moreover, rising demand for vaccine and an increase in the number of emerging markets will further provide beneficial opportunities for the rotavirus prophylaxis market growth during the forecast period.

Restraints/Challenges

On the other hand, the high cost associated with the treatment will obstruct the market's growth rate. The dearth of skilled professionals and lack of healthcare infrastructure in developing economies will challenge the rotavirus prophylaxis market. Additionally, a decline in clinical visits due to COVID-19 outbreak and lack of awareness among people will act as restrain and further impede the growth rate of market during the forecast period of 2022-2029.

This rotavirus prophylaxis market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the rotavirus prophylaxis market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Patient Epidemiology Analysis

Rotavirus prophylaxis market also provides you with detailed market analysis for patient analysis, prognosis and cures. Prevalence, incidence, mortality, adherence rates are some of the data variables that are available in the report. Direct or indirect impact analyses of epidemiology to market growth are analysed to create a more robust and cohort multivariate statistical model for forecasting the market in the growth period.

COVID-19 Impact on Rotavirus Prophylaxis Market

Since its emergence in December 2019, the COVID-19 virus has spread to nearly every country on the planet, prompting the World Health Organization (WHO) to declare it a public health emergency. Due to the financial crisis and the delay in specialty healthcare delivery while prioritizing COVID-19-related treatments, healthcare systems around the world were severely disrupted in the aftermath of the coronavirus pandemic. Patients were unable to see their controls for a variety of reasons, including difficulty accessing a doctor, fear of infection transmission, inability to continue therapies and essential procedures due to pandemic restrictions. Such considerations had a negative impact on the market of rotavirus prophylaxis.

Global Rotavirus Prophylaxis market Scope

The rotavirus prophylaxis market is segmented on the basis of treatment, route of administration, end-users and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Treatment

• Rotarix
• Rotavac
• Rotavin-M1
• Lanzhou Lamb
• Oral Rehydration Fluid
• Others

Route of Administration

• Oral
• Parenteral
• Others

End-Users

• Hospitals
• Specialty Clinics
• Homecare
• Others

Distribution Channel

• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy
• Others

Rotavirus Prophylaxis Market Regional Analysis/Insights

The Rotavirus prophylaxis market is analysed and market size insights and trends are provided by country, treatment, route of administration, end-users and distribution channel as referenced above.

The countries covered in the Rotavirus prophylaxis market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America

North America dominates the rotavirus prophylaxis market because of the growing prevalence of rotavirus and surging demand for disease-specific treatment. Additionally, presence of well-established healthcare infrastructure and growing awareness among patients will further propel the market’s growth rate in this region.

Asia-Pacific are expected to grow during the forecast period of 2022 to 2029 due to the increasing number of generic manufacturers and rising healthcare expenditure in this region. Furthermore, growing level of disposable income will further propel the market’s growth rate in this region.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.   

Competitive Landscape and Rotavirus Prophylaxis Market Share Analysis

The Rotavirus prophylaxis market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to rotavirus prophylaxis market.

Some of the major players operating in the rotavirus prophylaxis market are:

• Sanofi (France)
• Pfizer Inc. (US)
• GlaxoSmithKline plc (UK)
• 노바티스 AG(스위스)
• 머크앤코(미국)
• Bharat Serums and Vaccines Limited(인도)
• Bharat Biotech(인도)
• QIMR Berghofer 의학 연구소(호주)
• Serum Institute of India Pvt. Ltd. (인도)
• Biological E Limited(인도)
• Bio Farma(인도네시아)
• 아스텔라스파마 주식회사(일본)
• CSL Limited(호주)
• 존슨앤존슨 프라이빗 리미티드(미국)
• 다이이치 산쿄 주식회사(일본)
• 미쓰비시 타나베 파마 주식회사(일본)
• 아스트라제네카(영국)

SKU-53516